A biologics license application was resubmitted to the FDA by Amgen for Evenity, or romosozumab, being developed to treat postmenopausal women with osteoporosis who are at high risk of fracture. The filing included results from late-stage studies ARCH and BRIDGE.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.